Liu, Zheng-Zhao
Huang, Yan
Hong, Chun-Gu
Wang, Xin
Duan, Ran
Liu, Jian-Yang
He, Jia-Lin
Duan, Da
Xie, Hui
Funding for this research was provided by:
National Natural Science Foundation of China (82172502, 81974127, 81871822, 82101544)
Natural Science Foundation of Hunan Province (2021JJ40368)
Key project of Hunan Provincial Maternal and Child Health Care Hospital (2021RX01)
Article History
Received: 30 June 2022
Accepted: 18 August 2023
First Online: 7 September 2023
Declarations
:
: This human clinical study was approved by the Ethics Committee of the Second Affiliated Hospital of Hunan Normal University (Changsha, China, approval number: 2021389) on January 1, 2014. The approved title is: Research on clinical study and animal experiment of Autologous olfactory mucosa mesenchymal stem cells for treatment of chronic refractory epilepsy. The research complies with the Declaration of Helsinki. The trial was registered at Chinese Clinical Trial Registry () with reference number ChiCTR2200055357. Informed consent was obtained from all participants. All animal procedures were performed in agreement with the National Institutes of Health guidelines. The animal research was approved by the Ethical Review Board at Xiangya Hospital of Central South University which also approved the procedures involving animals (Changsha, China, approval number: 2017121175) on December 28, 2017. The approved title is: Mechanism of olfactory mucosal mesenchymal stem cells in the treatment of spinal cord injury, AD, epilepsy and pulmonary fibrosis.
: The subject participating in the personal image acquisition and clinical details signed the statement of consent form.
: The authors have no conflicts of interest to declare. The funding body (82172502, 81974127, 82101544, 2021JJ40368, 2021RX01) took part in the design of the study and collection, analysis, and interpretation of data and the writing of the manuscript; the funding body (81871822) took part in the consultant of the study and revision of the manuscript.